Abstract:Fusion proteins have the potential to become the new norm for targeted therapeutic treatments. Highly specific payload delivery can be achieved by combining custom targeting moieties, such as VHH domains, with active parts of proteins that have a particular activity not naturally targeted to the intended cells. Conversely, novel drug products may make use of the highly specific targeting properties of naturally occurring proteins and combine them with custom payloads. When designing such a product, there is rarely a known structure for the final construct which makes it difficult to assess molecular behaviour that may ultimately impact therapeutic outcome. Considering the time and cost of expressing a construct, optimising the purification procedure, obtaining sufficient quantities for biophysical characterisation, and performing structural studies in vitro, there is an enormous benefit to conduct in silico studies ahead of wet lab work. By following a repeatable, streamlined, and fast workflow of molecular dynamics assessment, it is possible to eliminate low-performing candidates from costly experimental work. There are, however, many aspects to consider when designing a novel fusion protein and it is crucial not to overlook some elements. In this work, we suggest a set of user-friendly, open-source methods which can be used to screen fusion protein candidates from the sequence alone. We used the light chain and translocation domain of botulinum toxin A (BoNT/A) fused with a selected VHH domain, termed here LC-HN-VHH, as a case study for a general approach to designing, modelling, and simulating fusion proteins. Its behaviour in silico correlated well with initial in vitro work, with SEC HPLC showing multiple protein states in solution and a dynamic protein shifting between these states over time without loss of material.

De novo Design of A Fusion Protein Tool for GPCR Research

[Single-Particle Cryo-Electron Microscopy Opens New Avenues in Structural Biology of G Protein-Coupled Receptor].

Rational Design of Drugs Targeting G-Protein-Coupled Receptors: A Structural Biology Perspective

Fragment-Based Computational Method for Designing GPCR Ligands

Protein Fusion Strategies for Membrane Protein Stabilization and Crystal Structure Determination

An open source in silico workflow to assist in the design of fusion proteins

Development of “plug and Play” Fiducial Marks for Structural Studies of GPCR Signaling Complexes by Single-Particle Cryo-EM

G protein-coupled receptors: structure- and function-based drug discovery

GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

Engineering G protein‐coupled receptors for stabilization

Recent Progress Using De Novo Design to Study Protein Structure, Design and Binding Interactions

Cryo-EM advances in GPCR structure determination

State-specific Peptide Design Targeting G Protein-coupled Receptors

Optimizing cryo-EM structural analysis of Gi-coupling receptors via engineered Gt and Nb35 application

A method for structure determination of GPCRs in various states

Development of an antibody fragment that stabilizes GPCR/G-protein complexes

Chimeric single α-helical domains as rigid fusion protein connections for protein nanotechnology and structural biology

Towards Structure-Based Protein Drug Design

A generic selection system for improved expression and thermostability of G protein-coupled receptors by directed evolution

GPCR structural characterization by NMR spectroscopy in solution